Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
03 Aug 2021
Historique:
received: 08 03 2021
accepted: 12 05 2021
entrez: 4 8 2021
pubmed: 5 8 2021
medline: 11 1 2022
Statut: epublish

Résumé

Quality assurance (QA) of treatment plans in clinical trials improves protocol compliance and patient outcomes. Retrospective use of knowledge-based-planning (KBP) in clinical trials has demonstrated improved treatment plan quality and consistency. We report the results of prospective use of KBP for real-time QA of treatment plan quality in the TROG 15.03 FASTRACK II trial, which evaluates efficacy of stereotactic ablative body radiotherapy (SABR) for kidney cancer. A KBP model was generated based on single institution data. For each patient in the KBP phase (open to the last 31 patients in the trial), the treating centre submitted treatment plans 7 days prior to treatment. A treatment plan was created by using the KBP model, which was compared with the submitted plan for each organ-at-risk (OAR) dose constraint. A report comparing each plan for each OAR constraint was provided to the submitting centre within 24 h of receiving the plan. The centre could then modify the plan based on the KBP report, or continue with the existing plan. Real-time feedback using KBP was provided in 24/31 cases. Consistent plan quality was in general achieved between KBP and the submitted plan. KBP review resulted in replan and improvement of OAR dosimetry in two patients. All centres indicated that the feedback was a useful QA check of their treatment plan. KBP for real-time treatment plan review was feasible for 24/31 cases, and demonstrated ability to improve treatment plan quality in two cases. Challenges include integration of KBP feedback into clinical timelines, interpretation of KBP results with respect to clinical trade-offs, and determination of appropriate plan quality improvement criteria.

Identifiants

pubmed: 34344402
doi: 10.1186/s13014-021-01820-7
pii: 10.1186/s13014-021-01820-7
pmc: PMC8330099
doi:

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

142

Informations de copyright

© 2021. The Author(s).

Références

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1114-1123
pubmed: 31002942
Radiother Oncol. 2016 Mar;118(3):540-6
pubmed: 26873790
Phys Imaging Radiat Oncol. 2019 Aug 08;11:34-40
pubmed: 33458275
BJU Int. 2017 Nov;120(5):623-630
pubmed: 28188682
Radiat Oncol. 2015 Nov 19;10:234
pubmed: 26584574
Pract Radiat Oncol. 2015 Nov-Dec;5(6):e597-605
pubmed: 26547828
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):545-51
pubmed: 21277097
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):176-81
pubmed: 23623460
Radiother Oncol. 2019 Jan;130:75-81
pubmed: 30348462
BMC Cancer. 2018 Oct 23;18(1):1030
pubmed: 30352550
J Natl Cancer Inst. 2013 Mar 20;105(6):387-93
pubmed: 23468460
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
J Clin Oncol. 2010 Jun 20;28(18):2996-3001
pubmed: 20479390
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):612-20
pubmed: 25680603
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):164-172
pubmed: 27979445
Semin Radiat Oncol. 2020 Oct;30(4):328-339
pubmed: 32828388
Pract Radiat Oncol. 2019 Mar;9(2):e218-e227
pubmed: 30562615
Br J Radiol. 2018 May;91(1085):20170737
pubmed: 29446317
Adv Radiat Oncol. 2020 May 22;5(6):1342-1349
pubmed: 33305097
Radiother Oncol. 2016 Aug;120(2):349-55
pubmed: 27394695
Med Phys. 2012 Dec;39(12):7446-61
pubmed: 23231294
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):941-949
pubmed: 32562838
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):246-60
pubmed: 23683829
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1067-1074
pubmed: 29485048
Med Phys. 2019 Jun;46(6):2760-2775
pubmed: 30963580
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):228-35
pubmed: 25847605

Auteurs

Nicholas Hardcastle (N)

Physical Sciences, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. nick.hardcastle@petermac.org.
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia. nick.hardcastle@petermac.org.
Department of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, Australia. nick.hardcastle@petermac.org.

Olivia Cook (O)

Trans Tasman Radiation Oncology Group, Newcastle, Australia.

Xenia Ray (X)

Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, USA.

Alisha Moore (A)

Trans Tasman Radiation Oncology Group, Newcastle, Australia.

Kevin L Moore (KL)

Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, USA.

David Pryor (D)

Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia.

Alana Rossi (A)

Trans Tasman Radiation Oncology Group, Newcastle, Australia.

Farshad Foroudi (F)

Olivia Newton, John Cancer Centre at Austin Health, Heidelberg, Australia.

Tomas Kron (T)

Physical Sciences, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia.
Department of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, Australia.

Shankar Siva (S)

Department of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, Australia.
Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH